Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial

Rituximab is often used as rescue therapy in interstitial lung disease (ILD) associated with connective tissue disease (CTD), but has not been studied in clinical trials. This study aimed to assess whether rituximab is superior to cyclophosphamide as a treatment for severe or progressive CTD associa...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Toby M. Maher, Veronica A Tudor, Peter Saunders, Michael Gibbons, Sophie Fletcher, Christopher P. Denton, Rachel K. Hoyles, Helen Parfrey, Elisabetta Renzoni, Maria Kokosi, Athol U. Wells, Deborah Ashby, Mátyás Szigeti, Philip L. Molyneaux, Mohammed Akil, Daphne Babalis, Nazia Chaudhuri, Felix Chua, Arnab Data, Dhananjay Desai, Shrish Dubey, Natalie Dwyer, Marcus Flather, Richard Fordham, Carlota M. Grossi, Frances Hall, Ira Jakupovic, Gregory J. Keir, Bipen D. Patel, Henry Penn, Arvind Rajasekaran, Lisa Spencer, Vicky Tsipouri, Zhe Wu, Georgio Xydopoulos, Fernando Zanghelini
Fformat: Artigo
Iaith:Saesneg
Cyhoeddwyd: 2022
Mynediad Ar-lein:https://doi.org/10.1016/s2213-2600(22)00359-9
http://www.thelancet.com/article/S2213260022003599/pdf
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Rhyngrwyd

https://doi.org/10.1016/s2213-2600(22)00359-9
http://www.thelancet.com/article/S2213260022003599/pdf

Eitemau Tebyg